For sort 2 diabetes patients with diligent albuminuria, including liraglutide, a glucagon-like peptide-1 receptor agonist, to treatment with renin-angiotensin framework (RAS) inhibitors may bring about a clinically significant lessening in 24-hour urinary egg whites discharge rate (UAER).
In a 12-week twofold visually impaired, traverse trial (ClinicalTrials.gov, NCT02545738), 27 patients with a urinary egg whites to-creatinine proportion (UAER) above 30 mg/g and evaluated glomerular filtration rate (eGFR) above 30 mL/min/1.73 m2 were haphazardly appointed to liraglutide (1.8 mg day by day) or fake treatment, with a 4-week washout period in the middle.
Keep READING BELOW
After fake treatment, the geometric mean UAER was 199 mg/24 hours, measured GFR was 75 mL/min/1.73m2, 24-hour circulatory strain (BP) was 145/80 mmHg, and hemoglobin A1c (HbA1c) was 61 mmoL/moL, as indicated by results distributed online in front of print in Diabetes Obesity and Metabolism. Liraglutide contrasted and fake treatment cut HbA1c by 8 mmoL/moL and weight by 1.8 kg more than 12 weeks. Liraglutide was connected with a 32% diminishment in UAER. The change in mGFR was - 5 mL/min/1.73m2 and was likely transitory. Change in 24-hour systolic BP was - 5 mmHg. A multivariate model discovered 24-hour systolic BP was connected with UAER. The examiners found no critical contrasts in levels of RAS hormones amongst liraglutide and fake treatment.
"By showing liraglutide treatment to decrease albuminuria by more than 30%, we recommend liraglutide as a novel treatment alternative with the capacity to lower albuminuria on top of existing RAS-hindrance in patients with constant albuminuria," Bernt Johan von Scholten, MD, of Steno Diabetes Center Niels Steensens in Gentofte Denmark, told Renal and Urology News. "Liraglutide may in this way be renoprotective and counteract movement of diabetic kidney ailment."
The impacts might be inferable from declines in BP, HbA1c, and plasma levels of renin focus and angiotensin II.
Extensive scale concentrates on looking at the long haul impacts of liraglutide and equivalent glucose-bringing down medications on movement in diabetic nephropathy are required. Half of patients reported unfriendly occasions, with 5 patients stopping the medication because of queasiness, heaving, or the runs.
The study was subsidized by Novo Nordisk, the producers of Victoza and Saxenda (liraglutide) a money related supporter of the Steno Diabetes Center, where a few study creators are utilized.
RELATED ARTICLES
Liraglutide, Sitagliptin Do Not Alter Renal Hemodynamics
Liraglutide Cuts CV Events in High-Risk Type 2 Diabetes Patients
Liraglutide as Add-on to Metformin Improves Glycemic Control
Source
1. 1. von Scholten BJ, Persson F, Rosenlund S, Hovind P, Faber J, Hansen TW, and Rossing P. The impact of liraglutide on renal capacity: A randomized clinical trial. Diabetes Obes Metab. 2016 Oct 17. doi: 10.1111/dom.12808. [Epub in front of print]
RELATED
Low HDL-C, High Triglycerides Up Risk for Diabetic Kidney Disease
AKI Risk Associated with Radiocontrast May Be Overestimated
Low Hemoglobin Associated With Elevated Risk of CIN
Saxagliptin Linked to Albuminuria Improvement
Investigate THE HAYMARKET MEDICAL NETWORK
Weakened Coronary Autonomic Measures Correlated With Reduced Coronary Flow in Diabetes
Cardiovascular Autonomic Function Linked to Coronary Flow Reserve in Type 2 Diabetes
SGLT-2 Inhibitors for Type 2 Diabetes: Renal and Urinary Issues
Impeded Cardiac Function Correlates With Reduced CFR in T2D
Controlled by
0
RELATED TOPICS
Albuminuria
Diabetes
Diabetic Nephropathy
RELATED LINKS
More in Diabetic Nephropathy
You should be an enrolled individual from Renal and Urology News to post a remark.
Click here to login | Click here to enroll
In a 12-week twofold visually impaired, traverse trial (ClinicalTrials.gov, NCT02545738), 27 patients with a urinary egg whites to-creatinine proportion (UAER) above 30 mg/g and evaluated glomerular filtration rate (eGFR) above 30 mL/min/1.73 m2 were haphazardly appointed to liraglutide (1.8 mg day by day) or fake treatment, with a 4-week washout period in the middle.
Keep READING BELOW
After fake treatment, the geometric mean UAER was 199 mg/24 hours, measured GFR was 75 mL/min/1.73m2, 24-hour circulatory strain (BP) was 145/80 mmHg, and hemoglobin A1c (HbA1c) was 61 mmoL/moL, as indicated by results distributed online in front of print in Diabetes Obesity and Metabolism. Liraglutide contrasted and fake treatment cut HbA1c by 8 mmoL/moL and weight by 1.8 kg more than 12 weeks. Liraglutide was connected with a 32% diminishment in UAER. The change in mGFR was - 5 mL/min/1.73m2 and was likely transitory. Change in 24-hour systolic BP was - 5 mmHg. A multivariate model discovered 24-hour systolic BP was connected with UAER. The examiners found no critical contrasts in levels of RAS hormones amongst liraglutide and fake treatment.
"By showing liraglutide treatment to decrease albuminuria by more than 30%, we recommend liraglutide as a novel treatment alternative with the capacity to lower albuminuria on top of existing RAS-hindrance in patients with constant albuminuria," Bernt Johan von Scholten, MD, of Steno Diabetes Center Niels Steensens in Gentofte Denmark, told Renal and Urology News. "Liraglutide may in this way be renoprotective and counteract movement of diabetic kidney ailment."
The impacts might be inferable from declines in BP, HbA1c, and plasma levels of renin focus and angiotensin II.
Extensive scale concentrates on looking at the long haul impacts of liraglutide and equivalent glucose-bringing down medications on movement in diabetic nephropathy are required. Half of patients reported unfriendly occasions, with 5 patients stopping the medication because of queasiness, heaving, or the runs.
The study was subsidized by Novo Nordisk, the producers of Victoza and Saxenda (liraglutide) a money related supporter of the Steno Diabetes Center, where a few study creators are utilized.
RELATED ARTICLES
Liraglutide, Sitagliptin Do Not Alter Renal Hemodynamics
Liraglutide Cuts CV Events in High-Risk Type 2 Diabetes Patients
Liraglutide as Add-on to Metformin Improves Glycemic Control
Source
1. 1. von Scholten BJ, Persson F, Rosenlund S, Hovind P, Faber J, Hansen TW, and Rossing P. The impact of liraglutide on renal capacity: A randomized clinical trial. Diabetes Obes Metab. 2016 Oct 17. doi: 10.1111/dom.12808. [Epub in front of print]
RELATED
Low HDL-C, High Triglycerides Up Risk for Diabetic Kidney Disease
AKI Risk Associated with Radiocontrast May Be Overestimated
Low Hemoglobin Associated With Elevated Risk of CIN
Saxagliptin Linked to Albuminuria Improvement
Investigate THE HAYMARKET MEDICAL NETWORK
Weakened Coronary Autonomic Measures Correlated With Reduced Coronary Flow in Diabetes
Cardiovascular Autonomic Function Linked to Coronary Flow Reserve in Type 2 Diabetes
SGLT-2 Inhibitors for Type 2 Diabetes: Renal and Urinary Issues
Impeded Cardiac Function Correlates With Reduced CFR in T2D
Controlled by
0
RELATED TOPICS
Albuminuria
Diabetes
Diabetic Nephropathy
RELATED LINKS
More in Diabetic Nephropathy
You should be an enrolled individual from Renal and Urology News to post a remark.
Click here to login | Click here to enroll
No comments:
Post a Comment
Note: only a member of this blog may post a comment.